Sana Biotechnology (NASDAQ:SANA – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Sunday.
SANA has been the subject of several other research reports. Rodman & Renshaw started coverage on shares of Sana Biotechnology in a research note on Monday, May 11th. They issued a “buy” rating and a $16.00 price objective for the company. Weiss Ratings cut shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Finally, Wedbush lifted their price target on shares of Sana Biotechnology from $6.00 to $7.00 and gave the company an “outperform” rating in a research report on Tuesday, April 14th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.50.
Check Out Our Latest Stock Analysis on Sana Biotechnology
Sana Biotechnology Stock Down 2.0%
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, equities research analysts predict that Sana Biotechnology will post -0.59 EPS for the current fiscal year.
Institutional Trading of Sana Biotechnology
Institutional investors and hedge funds have recently modified their holdings of the business. Royal Bank of Canada grew its position in shares of Sana Biotechnology by 76.8% in the first quarter. Royal Bank of Canada now owns 12,285 shares of the company’s stock valued at $35,000 after purchasing an additional 5,338 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $36,000. Rockefeller Capital Management L.P. lifted its stake in Sana Biotechnology by 74.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company’s stock valued at $39,000 after buying an additional 4,088 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in Sana Biotechnology in the 3rd quarter valued at approximately $39,000. Finally, LRI Investments LLC acquired a new stake in Sana Biotechnology during the 4th quarter valued at $41,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.
About Sana Biotechnology
Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.
The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.
Featured Stories
- Five stocks we like better than Sana Biotechnology
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
